Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

Euro Surveill. 2024 Mar;29(10). doi: 10.2807/1560-7917.ES.2024.29.10.2400109.ABSTRACTWe estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23-55) in 18-59-year-olds and 50% (95% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8-2.6).PMID:38456217 | DOI:10.2807/1560-7917.ES.2024.29.10.2400109

Source: Euro Surveill - March 8, 2024 Category: Infectious Diseases Authors: Anne J Huiberts Christina E Hoeve Brechje de Gier Jeroen Cremer Bas van der Veer Hester E de Melker Janneke Hhm van de Wijgert Susan van den Hof Dirk Eggink Mirjam J Knol Source Type: research